Florida Eye Associates | Melbourne, FL

Research site

(Unclaimed)

Location

502 East New Haven Avenue, Melbourne, Florida, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

KSI-301

Lampalizumab

Aflibercept

KHK4951

Faricimab

Zimura

AGN-190584

BI 771716

Avacincaptad pegol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 40 total trials

4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling

Neovascular (Wet) Age-Related Macular Degeneration

Biological: 4D-150 IVT

Biological: Aflibercept IVT

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW2)

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling

Non-proliferative Diabetic Retinopathy

Drug: Tarcocimab

Other: Sham injection

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting

Macular Edema Secondary to Retinal Vein Occlusion

Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

Drug: Sham

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Active, not recruiting

Edema

Diabetic Macular Edema

Drug: foselutoclax

Drug: Aflibercept

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling

Neovascular Age-Related Macular Degeneration

Drug: PDS Implant with Ranibizumab 100 mg/mL